Predictors of Clinical Progression among HIV-1–Positive Patients starting HAART with CD4+ T-cell Counts ≥200 cells/mm3
暂无分享,去创建一个
Carlo Torti | Massimo Di Pietro | Lorenzo Minoli | L. Minoli | C. Torti | G. Carosi | E. Quiros-Roldan | G. Lapadula | Giampiero Carosi | F. Maggiolo | F. Suter | Laura Sighinolfi | Eugenia Quiros-Roldan | Franco Maggiolo | Fredy Suter | S. Costarelli | G. Migliorino | Nicoletta Ladisa | Giuseppe Lapadula | Silvia Costarelli | Salvatore Casari | Chiara Pezzoli | Guglielmo Migliorino | S. Casari | L. Sighinolfi | N. Ladisa | M. Pietro | Chiara Pezzoli
[1] S. Shafran. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. , 2007, Journal of acquired immune deficiency syndromes.
[2] B. Gazzard,et al. When should antiretroviral therapy for HIV be started? , 2007, BMJ : British Medical Journal.
[3] B. Gazzard,et al. British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005) , 2005, HIV medicine.
[4] A. Mocroft,et al. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. , 2006, The Journal of infectious diseases.
[5] Jonathan AC Sterne,et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.
[6] B. Gazzard. British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.
[7] J. Neaton,et al. Comparison of Prognostic Importance of Latest CD4+ Cell Count and HIV RNA Levels in Patients with Advanced HIV Infection on Highly Active Antiretroviral Therapy , 2005, HIV clinical trials.
[8] V. Soriano,et al. Erratum: Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel (AIDS (2005) 19 (221-240)) , 2005 .
[9] J. Sterne,et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. , 2005, Archives of internal medicine.
[10] D. Vlahov,et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. , 2004, The Journal of infectious diseases.
[11] R. D’Aquila,et al. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy , 2004, Journal of acquired immune deficiency syndromes.
[12] Michael S Saag,et al. Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .
[13] J. Sterne,et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies , 2003, The Lancet.
[14] Hélène Jacqmin-Gadda,et al. Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001. , 2003, Journal of acquired immune deficiency syndromes.
[15] A. Phillips,et al. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era , 2003, AIDS.
[16] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[17] Julio S. G. Montaner,et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.
[18] Concerted Action on SeroConversion to Aids and Death in Europe. Is the Time From HIV Seroconversion a Determinant of the Risk of AIDS After Adjustment for Updated CD4 Cell Counts? , 2001, Journal of acquired immune deficiency syndromes.
[19] J Leibowitch,et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.
[20] J. Rodríguez-Orengo,et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. , 2006, Journal of hepatology.
[21] S. Cole,et al. Can we estimate the optimum CD4 threshold for starting HAART in antiretroviral-naïve HIV-infected individuals? , 2005 .
[22] C. Katlama,et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. , 2002, AIDS.